- Rec. PTP +9% vs. ABGSCe - Value changes positive, first time since Q4'22 - Earnings capacity IFPM ...
Redeye concludes that Q2 was stronger than Redeye had expected and, in fact, the strongest quarter i...
Redeye states that the Q2 report once again confirmed that Enea is back.
Redeye provides a research update following the Q2 report recently published by Magle.
Redeye updates its estimates and valuation following ADDvise releasing its Q2 2024 report, which fea...
Svedbergs Group released a solid Q2, growing its top line by 23% y/y and adjusted EBITA by 31%, prim...
Fiskars' Q2 adjusted EBIT came in largely in line with LSEG Data & Analytics consensus expectations ...
Redeye makes minor revisions based on the Q2 report.
- We raise '24e-'26e adj. EBIT by 3-1% - Conducive conditions for organic growth - Trading at NTM EV...
- Order intake -4% y-o-y on customer delays - We cut '24e-'26e sales by 7-5% but increase GMs - EBIT...
- Factory sales more than doubled - We raise '24-'26e EBITA by 7-6% - Share trading at 8x-6x our '24...
- A sizeable margin improvement in both segments - EBITA estimates left largely unchanged - Trading ...
- Medicare expands lower-limb prosthetics coverage from 1 Sep - Good news for patients and Embla Med...
- More focus on growth - Market still a headwind, but positive signs emerging - We raise '24e-'25e E...
Redeye increase our growth expectations for the long term while making minor adjustments for the nea...
Redeye strengthens its positive view of Vertiseit following a solid Q2 report, with 21% ARR growth a...
Redeye makes minor estimate revisions following Arise’s Q2 report, which was very much in line with ...
- Q2: 23% y-o-y ARR growth and 16% adj. EBITDA margin - FY'24 guidance raised for the third time YTD...
Hansa’s Q2 sales confirm a period of continuing progress.
Innofactor’s Q2 results fell below our expectations both due to a minor net sales decline and one-of...
